Prevention Of No-reflow Phenomenon Research Articles

The mechanism of exogenous adiponectin in the prevention of no-reflow phenomenon in type 2 diabetic patients with acute myocardial infarction during PCI treatment.

The article "The mechanism of exogenous adiponectin in the prevention of no-reflow phenomenon in type 2 diabetic patients with acute myocardial infarction during PCI treatment, by C.-J. Zhang, Y.-Z. Deng, Y.-H. Lei, J.-B. Zhao, W. Wei, Y.-H. Li, published in Eur Rev Med Pharmacol Sci 2018; 22 (7): 2169-2174-DOI: 10.26355/eurrev_201804_14751-PMID: 29687877" has been withdrawn from the authors due to some technical reasons (the authors still have not figured out how to address them). The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/14751.

The mechanism of exogenous adiponectin in the prevention of no-reflow phenomenon in type 2 diabetic patients with acute myocardial infarction during PCI treatment.

To investigate the mechanism of exogenous adiponectin in the prevention of no-reflow phenomenon in type 2 diabetic (T2DM) patients with acute myocardial infarction (AMI) during percutaneous coronary intervention (PCI) treatment. 66 patients were randomly divided into control group and observation group, 33 cases in each group. According to the percutaneous coronary intervention (PCI) emergency treatment principle, patients from the control group were treated with an intracoronary injection of adenosine combined with a micro-pump intravenous infusion of tirofiban. Patients from the observation group were injected with exogenous adiponectin in addition to the adenosine and tirofiban treatments. There were no significant differences in gender, age, location of the target lesion, degree of stenosis, stent implantation number, length and the inner diameter between control and observation group (p > 0.05). Lower frequent of slow blood flow and no-reflow and shorter interventional procedures were observed in observation group compared with those of control group (p < 0.05). Moreover, the increase of plasma creatine kinase (CK-MB) in patients of observation group was lower than that of the patients in control group (p < 0.05). In addition, the levels of troponin-I (cTnI), IL-6, TNF- α, endothelin-1 (ET-1), vascular endothelial adhesion molecular I (VCAM-1) and bax/Bcl-2 were significantly lower in observation group than those in control (p < 0.05). Furthermore, the occurrence of major adverse cardiac events (MACE) during a 12-month follow-up was significantly lower in the observation group than that of control (p < 0.05). Exogenous adiponectin further reduced the no-reflow phenomenon during PCI treatment of the patients with T2DM combined with AMI. The function of exogenous adiponectin is associated with the reduced myocardial and endothelial cell injury and the inhibited inflammation and apoptosis. The application of exogenous adiponectin can significantly improve the clinical outcomes.

Prevention of no-reflow phenomenon in culprit lesions involving a large side branch

No-reflow/slow-flow phenomenon (NF) is a poor prognostic factor in patients undergoing percutaneous coronary intervention. Distal protection devices (DPDs) prevent myocardial injury due to microembolic debris. When the target lesion involves a large side branch, DPDs can only protect the main vessel but not the side branch. In the present report, we describe the use of a two-step deflation in kissing-balloon technique for preventing NF in 4 patients (M/F = 4/0, 65 ± 6 years) in which the culprit lesions with NF risk involved a bifurcation. The procedures were uneventful and the 4 patients were discharged ≤24 h without ECG change and elevation of serum level of creatine kinase. The sequential deflation of kissing-balloon technique may constitute a possible solution for the NF related with the side branch on bifurcation lesions.

Successful prevention of no-reflow phenomenon in a high-risk patient using excimer laser coronary atherectomy

During the treatment of coronary artery disease, the no-reflow phenomenon can lead to severe impairment of viable cardiac muscle and all necessary measures should be taken to prevent it. Excimer laser coronary atherectomy (ELCA) may be indicated for lesions with a large thrombus burden due to potential to ablate thrombi and necrotic plaques. However, there are few reports on the use of ELCA for the prevention of distal embolism. Here, we report a case involving severe left ventricular dysfunction with a previous extensive anterior infarction, where ELCA was used in the right coronary artery to prevent the no-reflow phenomenon.